Company AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 10:10:22 2024-04-23 am EDT			5-day change	1st Jan Change
0.764 ^USD	+0.13%		+4.68%	+13.17%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Number of employees: 112

Managers	Title	Age	Since
Juan F. Vera FOU	Founder	44	13-07-31
Ann M. Leen FOU	Founder	47	13-07-31
Diana Brainard CEO	Chief Executive Officer	53	19-03-31
David Hallal CHM	Chairman	57	18-08-31
Vikas Sinha PSD	President	60	18-08-31
Brett Hagen AUD	Comptroller/Controller/Auditor	51	18-12-31
Edward Miller LAW	General Counsel	59	18-12-31

Members of the board	Title	Age	Since
Vikas Sinha PSD	President	60	18-08-31
Morana Jovan-Embiricos BRD	Director/Board Member	57	19-04-30
David Hallal CHM	Chairman	57	18-08-31
Jeffrey Bornstein BRD	Director/Board Member	57	20-06-30
Shawn Tomasello BRD	Director/Board Member	65	22-03-28
Derek Adams BRD	Director/Board Member	50	23-02-28
Diana Brainard CEO	Chief Executive Officer	53	19-03-31
Malcolm K. Brenner FOU	Founder	72	13-07-31
Juan F. Vera FOU	Founder	44	13-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	114,153,538	58,227,316 ( 51.01 %)	0	51.01 %

Name	Equities	%	Valuation
ElevateBio LLC 14.62 %	16,674,766	14.62 %	13 M $
GILEAD SCIENCES, INC. 14.58 %	16,635,286	14.58 %	13 M $
EcoR1 Capital, LLC 9.342 %	10,655,366	9.342 %	8 M $
Morana Jovan-Embiricos 6.126 %	6,987,027	6.126 %	5 M $
Artal Group SA 5.784 %	6,597,167	5.784 %	5 M $
Fidelity Management & Research Co. LLC 4.991 %	5,692,782	4.991 %	4 M $
John Wilson 4.696 %	5,355,877	4.696 %	4 M $
Millennium Management LLC 3.423 %	3,904,009	3.423 %	3 M $
BlackRock Advisors LLC 2.971 %	3,388,334	2.971 %	3 M $
David Hallal 2.602 %	2,967,780	2.602 %	2 M $

AlloVir, Inc.

1100 Winter Street

02451, Waltham

http://www.allovir.com

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.763 USD

Average target price

1 USD

Spread / Average Target

+31.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+12.24%	85.16M
VERTEX PHARMACEUTICALS INCORPORATED	-1.71%	103B
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.03%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-6.36%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B

Bio Therapeutic Drugs